Kala Bio faces Nasdaq delisting after stock trades below $1 for 30 days
K
KALA• Next steps and listing risk
- A hearing request to the Nasdaq Hearings Panel is planned; a timely filing would stay suspension or delisting pending a decision.
- Continued listing remains uncertain, raising delisting risk from the Nasdaq Capital Market.
Nasdaq minimum bid price deficiency
- Kala Bio received a Nasdaq staff determination letter on Aug. 27, 2026 for failing the $1 minimum bid price rule.
- Shares closed below $1 for 30 consecutive business days from July 16, 2026 through Aug. 26, 2026.
- Nasdaq denied the standard 180-day cure period because the company completed a 1-for-50 reverse split on May 11, 2026.
